Rosemarie Day & Me invite you to see Atul Gawande
My friend Rosemarie Day joins me to talk about the Healthcare Leaders for Democracy session…
Rosemarie Day & Me invite you to see Atul Gawande
My friend Rosemarie Day joins me to talk about the Healthcare Leaders for Democracy session coming up on September 4 (Thursday) at 8pm ET 5pm PT. It’s a one hour session with Atul Gawande as the keynote speaker, joined by Don Berwick and John McDonough. It’ll be a fascinating discussion and it’s a fundraiser for…
First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen?
Precigen’s Papzimeos is the first FDA-approved drug for the rare disease recurrent respiratory papillomatosis, or RRP. While this immunotherapy carries blockbuster expectations, Precigen’s financial reports indicate budgetary challenges. The post First Therapy for Rare Tumor Is a Blockbuster Prospect, But Does Precigen Have the Cash to Make It Happen? appeared first on MedCity News.
Insurers are Pulling Back on MA. How Does this Affect Patients?
Many insurers seem to be retreating from Medicare Advantage by exiting unprofitable markets and reducing benefits. This could be extremely disruptive to patients, experts warn. The post Insurers are Pulling Back on MA. How Does this Affect Patients? appeared first on MedCity News.
AI Meets Care Transitions: How One Startup Is Seeking to Reduce Readmissions and Costs
Boston-based startup Cascala Health raised an $8.6 million seed round to expand its AI platform for risk-bearing providers. The platform is designed to make patient care transitions safer and more efficient, as well as to help care teams spot risks earlier. The post AI Meets Care Transitions: How One Startup Is Seeking to Reduce Readmissions…
After Wegovy’s Historic MASH Approval, What’s Next?
Approval is only the beginning. Now comes the harder part: identifying the right patients, detecting the disease earlier, and monitoring outcomes so that this promising treatment is effective at scale. The post After Wegovy’s Historic MASH Approval, What’s Next? appeared first on MedCity News.
Secretary Kennedy’s Pride and Prejudice
His longstanding anti-vaccine rhetoric and vocal opposition to science-backed expert consensus has caused widespread concern among public health and medical professionals about the appropriateness of his leadership. The post Secretary Kennedy’s Pride and Prejudice appeared first on MedCity News.
Develop Health Secures $14.3M to Streamline Prior Authorization
Develop Health’s Series A funding round was led by Wing Venture Capital, and included participation from Afore Capital, J Ventures and South Park Commons. The post Develop Health Secures $14.3M to Streamline Prior Authorization appeared first on MedCity News.
In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug
The FDA approved Ionis Pharmaceuticals’ Dawnzera for preventing swelling attacks caused by the rare disease hereditary angioedema. A Takeda Pharmaceutical product dominates this market, but Ionis has clinical data showing patients had better outcomes after switching to Dawnzera from Takeda’s drug and other currently available HAE medications. The post In Crowded Market for a Rare…
Kennedy Takes Aim at Vaccine Injury Compensation Program
Health and Human Services Secretary Robert F. Kennedy Jr. has been implementing an anti-vaccine strategy that includes targeting a federal program that pays money to patients injured by immunizations, people familiar with the planning told KFF Health News. The plan involves expanding the types of injuries eligible for compensation, potentially overwhelming the fund with claims…
3 Announcements You Don’t Want to Miss from Epic’s Annual Meeting
At Epic’s annual Users Group Meeting, the EHR behemoth highlighted its growing AI strategy — announcing tools promising to benefit providers, payers and patients alike. The post 3 Announcements You Don’t Want to Miss from Epic’s Annual Meeting appeared first on MedCity News.
